This was confirmed by the rapid onset of anagen followed by hair growth in mouse and human skin after administering selective and reversible inhibitors of JAK1 and JAK2 an FDA-approved treatment option for the management of moderate-to-severe alopecia areata, autoimmune non-scarring alopecia [82, 83]. Here, JAK1 is linked to alopecia areata.